Stock Pick

Top brokers name 3 ASX shares to buy now

Written by

openjargon

in

Young man with a laptop in hand watching stocks and trends on a digital chart.

Many of Australia’s top brokers have been busy adjusting their financial models and recommendations. This has led to a number of broker notes being released this week.

Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:

4DMedical Ltd (ASX: 4DX)

According to a note out of Bell Potter, its analysts have retained their speculative buy rating on this medical technology company’s shares with an improved price target of $6.00. The broker highlights that 4DMedical has announced plans for a head to head study of its CT:VQ exam vs CT Pulmonary Angiogram (current standard of care) in patients with suspected Pulmonary Embolism (PE). It points out that this is necessary to generate clinical data to support the broader adoption of the 4DX CT:VQ exam for patients not subject to nuclear medicine for the ventilation/perfusion component of the exam. This is important because the total addressable market is estimated at $2.5 billion annually. And while changes to its earnings estimates are modest in the period before FY 2028, it expects exponential adoption beyond then. The 4DMedical share price is trading at $3.83 on Wednesday.

Coles Group Ltd (ASX: COL)

A note out of Macquarie reveals that its analysts have retained their outperform rating on this supermarket giant’s shares with an improved price target of $24.10. The broker believes that trading conditions are tough for retailers right now due to a significant weakening in the outlook for consumer spending. As a result, it has a preference for defensive retailers. This is particularly the case for supermarket operators, with Macquarie believing that consumers will cut back on spending in other categories but not on groceries. The Coles share price is fetching $21.48 at the time of writing.

Pro Medicus Ltd (ASX: PME)

Another note out of Macquarie reveals that its analysts have retained their outperform rating on this health imaging technology company’s shares with a trimmed price target of $221.00. This follows news that Pro Medicus has won a series of contracts for its Visage platform. Macquarie was pleased with the contract wins and highlights that one with TidalHealth includes its cardiology offering. It believes this leaves the company well-placed to achieve its market share estimates by 2030. And with its shares down heavily from their highs, the broker sees considerable upside for investors over the next 12 months. The Pro Medicus share price is trading at $159.12 on Wednesday.

The post Top brokers name 3 ASX shares to buy now appeared first on The Motley Fool Australia.

Should you invest $1,000 in 4DMedical right now?

Before you buy 4DMedical shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts